In the News

Three faculty members from Memorial Sloan Kettering Cancer Center (MSK) and Sloan Kettering Institute (SKI) have been elected to the 2021 class of American Association for the Advancement of Science (AAAS) Fellows.

For cancer in the liver, interventional radiology techniques can be used to destroy tumors while minimizing damage to healthy liver tissue. 

In a recent interview, MSK's Dr. Jeffrey Drebin addressed why it’s important for people to keep up with their routine screenings and not put off cancer treatment or surgery.

MSK researchers identified a protein called ZFP36L2 that acts as a critical "molecular switch" controlling how gut cells repair themselves after injury — a mechanism that colorectal cancer hijacks to spread to other organs. The findings could point toward new treatments that exploit cancer cells' dependence on this protein to stop metastasis or overcome treatment resistance.

The oncology community has stepped up to meet the challenges of the ongoing COVID-19 pandemic but must redouble their efforts in order to stem the potential long-term consequences of this public health crisis on the field.

Learn about larotrectinib, the first cancer drug to be FDA approved for adult and pediatric patients at the same time.

The research focused on sclerosing stromal tumor, a rare, benign ovarian tumor that is not cancer but can be misdiagnosed as cancer.

Topics included more diverse representation in clinical trials, racial disparities in colorectal cancer, and ancestry testing to improve diagnoses.

New MSK research uncovers why some leukemia patients stop responding to promising new drugs; examines how bone’s hardness shapes the immune battle against metastasis; shows how a telehealth tobacco treatment program helps cancer patients quit smoking; creates the first atomic-level images of a key phosphate transporter that could inform treatment of ovarian cancer and kidney disease; finds Medicare Advantage patients with cancer receive optimal treatment at lower cost; and studies how much tissue surgeons should remove for tumor-related epilepsy.

New MSK research uses saturation genome editing to better understanding of the RAD51C gene, which has been linked to higher risks of breast and ovarian cancer; sheds new light on brain metastasis; and finds a commercially available contrast dye could help surgeons better separate cancer from healthy tissue.